HilleVax Provides Update on P-IIb (NEST-IN1) Trial of HIL-214 to Prevent Acute Gastroenteritis (AGE) in Infants
Shots:
- The P-IIb (NEST-IN1) study is to find the safety, efficacy & immunogenicity of HIL-214 (n=1,425) vs PBO (n=1,399) among infants (age: 5mos.) during initial vaccination across the US & LATAM, with 51 1EPs
- Study did not reach its 1EP & 2EP demonstrating effectiveness of 5% against moderate or severe AGE events caused by GI.1 or GII.4 norovirus genotypes; safety & immunogenicity aligned with the prespecified analysis in the first 200 individuals across NEST-IN1 & prior studies
- The company plans to halt the NEST-IN1 trial in infants, conducted due to favorable results in P-IIb (NOR-211) among adults, and advance HIL-214 & P-I-ready HIL-216 vaccine for adult population
Ref: HilleVax | Image: HilleVax
Related News:- Vertex Receives CHMP’s Positive Opinion for Kalydeco as a Treatment of Cystic Fibrosis in Infants
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
